Aushon Biosystems' Multiplex Immunoassay Platform Used to Validate Panel of Prognostic and Predictive Protein Biomarkers in Recent Phase II and Phase III Studies  
6/10/2011 8:47:31 AM

BILLERICA, Mass.--(BUSINESS WIRE)--Data was presented at the recent American Society of Clinical Oncology's 2011 Genitourinary Cancers Symposium showing multiple protein biomarkers predictive of clinical benefit and prognostic of disease outcome in patients with advanced or metastatic renal cell cancer. This Phase III trial validated plasma cytokine and angiogenic biomarkers using Aushon’s multiplex immunoassay platform.